4.2 Article

TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer

Journal

ACTA HISTOCHEMICA
Volume 116, Issue 5, Pages 708-712

Publisher

ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.acthis.2013.12.009

Keywords

TRIM29; Prostate cancer; Basal cell; Human

Categories

Funding

  1. KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology in Japan [24112006, 24390065]
  2. Sumitomo Foundation
  3. Cosmetology Research Foundation
  4. Grants-in-Aid for Scientific Research [24112006, 24390065, 25670134] Funding Source: KAKEN

Ask authors/readers for more resources

Tripartite motif protein 29 (TRIM29) is one of the TRIM family proteins, some of which function as E3 ubiquitin ligases. In this study, we investigated the usefulness of TRIM29 for diagnosis of prostate cancer Prostate tissues including carcinoma and non-carcinoma tissues obtained by needle biopsy and radical prostatectomy were used. Immunohistochemistry was performed according to standard procedures using an antibody against TRIM29. Immunohistochemical staining with an antibody against 34 beta E12, which recognizes cytokeratins 1, 5, 10 and 14, was performed as a control. Basal cells of normal prostatic glands were stained with anti-TRIM29 antibody in all cases, whereas prostate cancer tissues had no or little staining with anti-TRIM29 antibody. TRIM29 is selectively expressed in basal cells of the normal prostate gland, and immunohistochemical staining with anti-TRIM29 antibody showed the same expression pattern as that with 34 beta E12 in prostate cancer and its benign mimics. Our data indicate that TRIM29 may be useful for distinguishing prostate cancers from benign tissues. (C) 2013 Elsevier GmbH. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available